76 related articles for article (PubMed ID: 22807211)
1. Fluorescence-labeled immunomicelles: preparation, in vivo biodistribution, and ability to cross the blood-brain barrier.
Yue J; Liu S; Wang R; Hu X; Xie Z; Huang Y; Jing X
Macromol Biosci; 2012 Sep; 12(9):1209-19. PubMed ID: 22807211
[TBL] [Abstract][Full Text] [Related]
2. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system.
Cerletti A; Drewe J; Fricker G; Eberle AN; Huwyler J
J Drug Target; 2000; 8(6):435-46. PubMed ID: 11328669
[TBL] [Abstract][Full Text] [Related]
3. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26.
Aktaş Y; Yemisci M; Andrieux K; Gürsoy RN; Alonso MJ; Fernandez-Megia E; Novoa-Carballal R; Quiñoá E; Riguera R; Sargon MF; Celik HH; Demir AS; Hincal AA; Dalkara T; Capan Y; Couvreur P
Bioconjug Chem; 2005; 16(6):1503-11. PubMed ID: 16287248
[TBL] [Abstract][Full Text] [Related]
4. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC
Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898
[TBL] [Abstract][Full Text] [Related]
5. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26.
Pang Z; Lu W; Gao H; Hu K; Chen J; Zhang C; Gao X; Jiang X; Zhu C
J Control Release; 2008 Jun; 128(2):120-7. PubMed ID: 18436327
[TBL] [Abstract][Full Text] [Related]
6. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.
Lee HJ; Engelhardt B; Lesley J; Bickel U; Pardridge WM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1048-52. PubMed ID: 10688622
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody.
Wu D; Pardridge WM
Drug Metab Dispos; 1998 Sep; 26(9):937-9. PubMed ID: 9733674
[TBL] [Abstract][Full Text] [Related]
8. Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate.
Kang YS; Pardridge WM
J Pharmacol Exp Ther; 1994 Apr; 269(1):344-50. PubMed ID: 8169841
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and brain uptake of lactoferrin in rats.
Ji B; Maeda J; Higuchi M; Inoue K; Akita H; Harashima H; Suhara T
Life Sci; 2006 Jan; 78(8):851-5. PubMed ID: 16165165
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of Baicalin-loaded cationic solid lipid nanoparticles conjugated with OX26 for improved delivery across the BBB.
Liu Z; Zhao H; Shu L; Zhang Y; Okeke C; Zhang L; Li J; Li N
Drug Dev Ind Pharm; 2015 Mar; 41(3):353-61. PubMed ID: 25784073
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
12. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Yoshikawa T; Pardridge WM
J Pharmacol Exp Ther; 1992 Nov; 263(2):897-903. PubMed ID: 1432704
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor.
Kang YS; Bickel U; Pardridge WM
Drug Metab Dispos; 1994; 22(1):99-105. PubMed ID: 8149897
[TBL] [Abstract][Full Text] [Related]
14. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion.
Gosk S; Vermehren C; Storm G; Moos T
J Cereb Blood Flow Metab; 2004 Nov; 24(11):1193-204. PubMed ID: 15545912
[TBL] [Abstract][Full Text] [Related]
15. Poly(ethylene glycol)-block-poly(D,L-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery.
Shen J; Zhan C; Xie C; Meng Q; Gu B; Li C; Zhang Y; Lu W
J Drug Target; 2011 Apr; 19(3):197-203. PubMed ID: 20446756
[TBL] [Abstract][Full Text] [Related]
16. PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting.
Monsalve Y; Tosi G; Ruozi B; Belletti D; Vilella A; Zoli M; Vandelli MA; Forni F; López BL; Sierra L
Nanomedicine (Lond); 2015; 10(11):1735-50. PubMed ID: 26080696
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.
Wu D; Pardridge WM
J Pharmacol Exp Ther; 1996 Oct; 279(1):77-83. PubMed ID: 8858978
[TBL] [Abstract][Full Text] [Related]
18. Folate-conjugated amphiphilic star-shaped block copolymers as targeted nanocarriers.
Zhu J; Zhou Z; Yang C; Kong D; Wan Y; Wang Z
J Biomed Mater Res A; 2011 Jun; 97(4):498-508. PubMed ID: 21509931
[TBL] [Abstract][Full Text] [Related]
19. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker.
Deguchi Y; Kurihara A; Pardridge WM
Bioconjug Chem; 1999; 10(1):32-7. PubMed ID: 9893961
[TBL] [Abstract][Full Text] [Related]
20. Brain targeting using novel lipid nanovectors.
Béduneau A; Hindré F; Clavreul A; Leroux JC; Saulnier P; Benoit JP
J Control Release; 2008 Feb; 126(1):44-9. PubMed ID: 18055056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
